Within some Japanese companies, there is resistance to disclosing attacks and upgrading systems, which stems from societal norms around assigning blame, some analysts say.
This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w